Lead Optimization: Integrating Experimental, Computational, and AI/ML Approaches

One of the most important and complex phases of drug development is lead optimization (LO), which turns early "hit" molecules into promising therapeutic candidates. The goal of this iterative approach is to reduce possible toxicity while improving a molecule's potency, selectivity, pharmacokinetics (ADME), and safety. In the past, LO depended on resource-intensive, empirical techniques. However, computational methods, especially virtual screening (VS), which includes structure-based (molecular docking and dynamics) and ligand-based (QSAR, pharmacophore modeling) approaches, have completely changed the area. These technologies aid in the logical design and synthesis of novel analogues by forecasting binding affinities and interaction patterns. Recent developments in artificial intelligence and machine learning are having a significant impact on LO, despite obstacles like precisely simulating receptor flexibility and desolvation effects. Generative Therapeutics Design (GTD) and Query-based molecular optimization (QMO) are two AI/ML-driven approaches that facilitate more effective chemical space exploration, improve the precision of molecular property predictions, and speed up the development of novel chemical entities. In order to overcome previous constraints and expedite the delivery of improved, safer, and more effective therapeutic candidates, this review examines the synergistic application of classic experimental, advanced computational, and transformative AI/ML approaches.